InVivo Therapeutics Announces Closing of $15.0 Million Public Offering
October 26 2020 - 4:15PM
Business Wire
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today
announced the closing of its previously announced public offering
of 18,750,000 shares of its common stock (or pre-funded warrants to
purchase common stock in lieu thereof), together with warrants to
purchase up to 18,750,000 shares of common stock at a combined
effective price to the public of $0.80 per share (or pre-funded
warrant) and associated warrant. The gross proceeds from this
offering were $15.0 million, before deducting the placement agent
fees and offering expenses payable by InVivo Therapeutics.
H.C. Wainwright & Co. acted as exclusive placement agent for
the offering.
A registration statement on Form S-1 (File No. 333-249353)
relating to these securities has been filed with the Securities and
Exchange Commission, or the SEC, and was declared effective by the
SEC on October 22, 2020. The offering was made only by means of a
prospectus, which is part of the effective registration statement.
Electronic copies of the final prospectus may be obtained for free
on the SEC’s website located at http://www.sec.gov and may also be
obtained by contacting H.C. Wainwright & Co., LLC, 430 Park
Avenue, 3rd Floor, New York, NY 10022, by telephone at (646)
975-6996 or by email to placements@hcwco.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or other jurisdiction in which such an offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or other jurisdiction.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. The
publicly traded company is headquartered in Cambridge, MA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201026005796/en/
IR CONTACT: Bret Shapiro, Managing Partner CORE IR Phone:
(516) 222-2560 brets@coreir.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Aug 2024 to Sep 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Sep 2023 to Sep 2024